BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...
BioAge Labs stock rose Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments.
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, ...
BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from ...